Shakir Sufyan, Choo-Kang Brian, Ross Clare, Conroy Kevin, Thorley Richard, Walker Steven, Bhatnagar Rahul, Aujayeb Avinash
Department of Respiratory Medicine, Northumbria Healthcare NHS Trust, Northumbria Way, Cramlington, NE23 6NZ, UK.
Department of Respiratory Medicine, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, G4 0SF, UK.
Pulm Ther. 2023 Mar;9(1):165-172. doi: 10.1007/s41030-022-00212-w. Epub 2022 Dec 30.
Treatment of prolonged air leak due to secondary spontaneous pneumothorax is challenging. Autologous blood patch pleurodesis (ABPP) is a treatment option. Previous evidence is reliant on single-centre series and underpowered trials and is mostly described in air leaks post cardiothoracic intervention. There are no United Kingdom (UK) wide data.
Members of the UK Pleural Society were surveyed for their practice and for patients who underwent blood patch. There were 16 respondents from 333 members. Twelve had performed the procedure, and six had kept records and could submit data. Basic demographics, intervention and clinical details of patients were then collected. The study was sponsored by the Audit Department of Northumbria Healthcare NHS Foundation Trust (reference 8124), and Caldicott Clearance for data sharing was provided by the Trust's Information Goverance Board (reference C4221). There was no requirement for informed consent.
Data for 12 patients that received ABPP between 2014 and 2022 in six respiratory centres were assessed. The aetiology of the secondary pneumothoraces was mostly due to chronic obstructive pulmonary disease and end-stage interstitial lung disease. The patients had a median age of 75 years. The median air leak time before ABPP was 17 days. A total of 50-100 ml of blood was used for ABPP. Five patients had two attempts at ABPP. Air leak resolved in six patients (50%). Four patients had pleural apposition prior to ABPP. Four patients were diagnosed with hospital-acquired pneumonia following ABPP.
This is the only UK-wide retrospective case series of ABPP of 'medical' patients with secondary pneumothorax. There is widespread variation in care. No formal conclusions can be drawn, and much larger robust datasets are required. An application has been made to the European Respiratory Society to incorporate ABPP within the International Collaborative Effusion database.
继发性自发性气胸导致的持续性漏气治疗颇具挑战性。自体血贴片胸膜固定术(ABPP)是一种治疗选择。以往的证据依赖于单中心系列研究和效能不足的试验,且大多描述的是心胸外科手术后的漏气情况。英国尚无全国范围的数据。
对英国胸膜协会的成员进行了关于其治疗方法以及接受血贴片治疗患者情况的调查。333名成员中有16人回复。其中12人实施了该手术,6人保存了记录并能提交数据。随后收集了患者的基本人口统计学信息、干预措施及临床细节。该研究由诺森伯兰医疗保健国民保健服务信托基金审计部赞助(参考编号8124),信托基金信息治理委员会提供了数据共享的考迪科特许可(参考编号C4221)。无需获得知情同意。
评估了2014年至2022年期间在六个呼吸中心接受ABPP治疗的12例患者的数据。继发性气胸的病因主要是慢性阻塞性肺疾病和终末期间质性肺疾病。患者的中位年龄为75岁。ABPP前的中位漏气时间为17天。ABPP共使用了50 - 100毫升血液。5例患者接受了两次ABPP尝试。6例患者(50%)的漏气情况得到解决。4例患者在ABPP前已有胸膜粘连。4例患者在ABPP后被诊断为医院获得性肺炎。
这是英国唯一一项关于“内科”继发性气胸患者ABPP的全国性回顾性病例系列研究。治疗方法存在广泛差异。无法得出正式结论,需要更大规模、可靠的数据集。已向欧洲呼吸学会申请将ABPP纳入国际协作性胸腔积液数据库。